In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


This content is past the free consultation date

It is only available to ACCA members, members with an all access option or Fellows of the ESC

It is only available to EACVI Members, members with an all access option or Fellows of the ESC

It is only available to EAPC Members, members with an all access option or Fellows of the ESC

It is only available to EAPCI Members, members with an all access option or Fellows of the ESC

It is only available to EHRA Members, members with an all access option or Fellows of the ESC

It is only available to HFA Members, members with an all access option or Fellows of the ESC

It is only available to ESC Pro members, members with an all access option or Fellows of the ESC

Get your access now Get your access now Get your access now Get your access now Get your access now Get your access now Get your access now
Myeloperoxidase-deficiency protects from ventricular tachycardia in a murine model of ischemic cardiomyopathy

Session Poster session 2

Speaker Volker Rudolph

Congress : ESC Congress

  • Topic : arrhythmias and device therapy
  • Sub-topic : Arrhythmias, General - Pathophysiology and Mechanisms
  • Session type : Poster Session
  • FP Number : P1445

Authors : V Rudolph (Cologne,DE), M Mollenhauer (Cologne,DE), A Klinke (Cologne,DE), L Remane (Cologne,DE), K Friedrichs (Cologne,DE), TK Rudolph (Cologne,DE), S Baldus (Cologne,DE)

15 views

Authors:
V. Rudolph1 , M. Mollenhauer1 , A. Klinke1 , L. Remane1 , K. Friedrichs1 , T.K. Rudolph1 , S. Baldus1 , 1Cologne University Hospital - Heart Center - Cologne - Germany ,

Citation:
European Heart Journal ( 2014 ) 35 ( Abstract Supplement ), 258

Background: Leukocytes have emerged as important mediators of adverse myocardial remodeling following myocardial infarction. Myeloperoxidase (MPO), a heme enzyme abundantly expressed and released by polymorphonuclear neutrophils (PMN), exerts pro-inflammatory and pro-fibrotic properties and has been identified to be causally linked to the formation and propagation of various cardiovascular disorders. We disclosed recently, that MPO critically promotes atrial fibrosis and arrhythmias. Thus, we sought to investigate whether MPO might also influence structural and electrical remodelling in ventricular myocardium.

Methods and results: Wild-type C57bl/6J (WT) and MPO-deficient (Mpo−/−) mice underwent either sham surgery (n=7, 6) or ligation of the left descending coronary artery (LAD) (n=7, 5). Right ventricular electrophysiological investigations 3 weeks after LAD ligation disclosed profoundly increased vulnerability for ventricular tachycardia (VT) in infarcted WT as compared to Mpo−/− mice (number of VT episodes: 6.7±1.3 vs. 1.8±0.9, p<0.01, sham: 2.0±0.4 vs. 1.7±0.8, p=0.79; total time of VT episodes: 3.67±0.88 vs. 0.88±0.36 sec, p<0.05, sham: 0.70±0.18 vs. 1.07±0.75 sec, p=0.67). Epicardial mapping analyses indicated a delayed velocity and enhanced heterogeneity of electrical conduction in WT as compared to Mpo−/− mice. No differences were observed in infarct size between WT and Mpo−/− mice, as assessed by hematoxylin/eosin stain of myocardial sections.

Conclusions: The current data demonstrate, that MPO increases the vulnerability for ventricular arrhythmias in a murine model of ischemic cardiomyopathy. Whereas no differences were observed in infarct size, characteristics of electrical conduction pointed to aggravated adverse electrical or structural remodeling in WT as compared to Mpo−/− mice. While the underlying mechanisms still have to be elucidated, the results underline the important role of inflammatory processes in cardiac remodeling upon myocardial infarction and identify MPO as a potential therapeutic target to prevent ventricular arrhythmias in ischemic cardiomyopathy.



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are